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Highly active antiretroviral therapy (HAART) is used in patients infected with HIV. This treatment has been 
shown to significantly decrease opportunist infections such as those caused by viruses, fungi and particularly, 
protozoa. The use of HAART in HIV-positive persons is associated with immune reconstitution as well as 
decreased prevalence of oral candidiasis and candidal carriage. Antiretroviral therapy benefits patients who are 
co-infected by the human immunodeficiency virus (HIV), human herpes virus 8 (HHV-8), Epstein-Barr virus, 
hepatitis B virus (HBV), parvovirus B19 and cytomegalovirus (CMV). HAART has also led to a significant 
reduction in the incidence, and the modification of characteristics, of bacteremia by etiological agents such as 
Staphylococcus aureus, coagulase negative staphylococcus, non-typhoid species of Salmonella, Streptococcus 
pneumoniae, Pseudomonas aeruginosa, and Mycobacterium tuberculosis. HAART can modify the natural 
history of cryptosporidiosis and microsporidiosis, and restore mucosal immunity, leading to the eradication of 
Cryptosporidium parvum. A similar restoration of immune response occurs in infections by Toxoplasma gondii. 
The decline in the incidence of visceral leishmaniasis/HIV co-infection can be observed after the introduction 
of protease inhibitor therapy. Current findings are highly relevant for clinical medicine and may serve to reduce 
the number of prescribed drugs thereby improving the quality of life of patients with opportunistic diseases.
Uniterms: Highly active antiretroviral therapy. Antiretroviral drugs/activity. Opportunist infections/treatment. 
A terapia HAART (terapia antirretroviral altamente ativa) é usada em pacientes infectados pelo vírus da 
imunodeficiência humana (HIV) e demonstrou diminuição significativa de infecções oportunistas, tais como 
as causadas por vírus, fungos, protozoários e bactérias. O uso da HAART está associado com a reconstituição 
imunológica e diminuição na prevalência de candidíase oral. A terapia antirretroviral beneficia pacientes co-
infectados pelo HIV, vírus herpes humano 8 (HHV-8), vírus Epstein-Barr (EBV), vírus da hepatite B (HBV), 
parvovírus B19 e citomegalovírus (CMV). A HAART também apresentou redução significativa da incidência e 
modificou as características da bacteremia por agentes etiológicos, tais como Staphylococcus aureus, espécies 
não-tifóides de Salmonella, Streptococcus pneumoniae, Pseudomonas aeruginosa, Mycobacterium tuberculosis. 
A HAART é capaz de modificar significativamente a história natural da criptosporidiose e microsporidiose. 
HAART pode efetivamente restaurar a imunidade da mucosa, levando à erradicação de Cryptosporidium parvum. 
Semelhante restauração da resposta imune ocorre em infecções por Toxoplasma gondii. O declínio na incidência 
de co-infecção leishmaniose visceral/HIV pode ser observada após a introdução da terapia com inibidores da 
protease. Os resultados atuais são altamente relevantes para a medicina clínica e podem proporcionar diminuição 
no número de prescrições medicamentosas e, consequentemente, melhor qualidade de vida para pacientes com 
doenças oportunistas.
Unitermos: Terapia antirretroviral altamente ativa. Medicamentos antirretrovirais/atividade. Infecções 
oportunistas/tratamento.
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INTRODUCTION
Combined antiretroviral (ARV) drugs have im-
proved survival rates in acquired immune deficiency 
syndrome (AIDS) patients. Early antiretroviral drugs 
caused only temporary gains due to low efficiency in the 
recovery of immune competence of the patient and to the 
limited effects in reducing viral load. The use of new ARV 
classes (protease inhibitors and non-nucleoside reverse 
transcriptase inhibitors) from the mid-1990s proved highly 
successful in HIV-infected persons through highly active 
antiretroviral therapy (HAART). A significant fall in AIDS 
morbidity and mortality rates were reported (Delpierre et 
al., 2008).
In developed countries, HAART has achieved sig-
nificant results in the suppression of HIV viral load and 
restoration of immunity, coupled with improvements in 
qualitative and quantitative CD4+ T-cells counts and with 
significant decreases in opportunist infections such as 
those caused by viruses, fungi and particularly, protozoa. 
Standout medicines include reverse transcriptase nucleo-
sides inhibitors and protease inhibitors (WHO, 2006).
Protease inhibitors block the activity of the aspartyl 
protease of the HIV and may affect the growth of other 
micro-organisms besides blocking virus multiplication 
(Abbenante, Fairlie, 2005). The activity of HIV protease 
inhibitors in Leishmania spp. (Savoia, Allice, Tovo, 2005), 
Toxoplasma gondii (Deuroin, Santillana-Hayat, 2000), 
Plasmodium spp. (Andrews et al., 2006; Parikh et al., 
2005; Redmond et al., 2007), Crypstosporidium parvum 
(Mele et al., 2003; Pozio, Morales, 2005), Candida albi-
cans (Falkensammer et al., 2007), and Mycobacterium 
spp. (Kabbesh et al., 2005), among others, has been pre-
viously shown. Reverse transcriptase inhibitors may also 
affect organisms such as Trypanosoma cruzi (Nakajima-
Shimada, Aoki, 1998).
The current systematic review identifies and ana-
lyzes original articles published in the literature on the 
activity of antiretroviral drugs in human infections by 
opportunist agents. 
METHODS
A systematic review of the databases PubMed 
(U.S. National Library of Medicine), SciELO (Scientific 
Electronic Library Online) and LILACS (Latin American 
and Caribbean Center on Information in Health Sciences) 
was undertaken from February to April 2008. This study 
focused on articles retrieved in English, French, Italian, 
Spanish and Portuguese languages, published between 
January 1998 and December 2007. Additional articles 
besides those identified in the systematic review were 
included in the discussion of the data.
Search strategy and quality assessment
The search strategy on PubMed consisted of em-
ploying the MeSH Database for the term ‘antiretroviral 
agents’ coupled to ‘fungi’, ‘bacteria’, ‘viruses’, ‘protozoa’, 
‘opportunistic infections’, using the limits of the method-
ological filter to identify original publications of clinical 
trials, randomized controlled trials, case reports, classical 
articles, comparative studies and journal articles. Although 
a free term search strategy was employed on the SciELO 
and LILACS databases, coupling ‘antiretroviral drugs’ 
and ‘fungus’, ‘bacteria’, ‘virus’, ‘protozoa’, ‘opportunist 
infections’, no reference was extant.
The first stage involving the bibliography focused on 
sample quality and quality of the analysis among identified 
publications. Two researchers independently undertook 
the same task on the electronic databases in order to in-
crease search precision. 
The second stage consisted of an analysis of poten-
tial articles by four independent researchers. This entailed 
examination of each article’s predefined contents, namely, 
aim, opportunist agent, study design, antiretroviral drugs, 
conclusion. Publications were chosen at random and al-
located to the four researchers for analysis. In addition, an 
additional search for relevant articles identified from the list 
of references of the initially retrieved papers was performed.
The third stage involved a further final randomized 
selection of article handed out to three researchers, or ‘in-
dependent judges,’ for verification of the total percentage 
of agreement with regard to contents from each article 
versus the four researchers’ predefined items.
Behavioral data
Figure 1 shows the potential publications for analysis 
by the current study. The 25 articles identified only on the 
PubMed database using the key word antiretroviral agent 
and the terms fungi, viruses, bacteria, protozoa were com-
bined in 6, 9, 5 and 5 publications, respectively. Antiretro-
viral combinations and opportunist infections/infectious 
were automatically classified for the respective opportunist 
agent group. Total percentage concordance among the three 
judges with regard to the four independent researchers was 
calculated as 72.7% (8/11), 75.0% (3/4) and 77.8% (7/9). 
Antiretroviral drugs and fungal agents (Table I)
HAART has produced satisfactory results in HIV 
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these drugs and antiretrovirals (Migliorati et al., 2004).
Antiretroviral treatment, including protease in-
hibitors, in patients with advanced HIV infection, has a 
positive impact on the natural history of oropharyngeal 
candidiasis (OPC). This positive impact appears to be 
correlated with improved immunological function in 
spite of constant HIV replication (Arribas et al., 2000). 
Consequently, decrease in colonization and oral manifesta-
tions has been reported in patients, with high CD4+ T-cell 
counts reported after PI employment (Hoegl et al., 1998).
The same protease inhibitors can act directly on 
SAPs 1, 2 and 3, but not on SAPs 4, 5 and 6, inhibiting 
several relevant biological processes of C. albicans, such 
as growth and adhesion to mammalian cells (Bektic et 
al., 2001; Blanco et al., 2003; Borg-von Zepelin et al., 
1999; Braga-Silva et al., 2010; Cassone et al., 1999; 
Falkensammer, Pilz, Bektic, 2007; Gruber et al., 1999; 
Korting et al., 1999; Monod et al., 1999). Braga-Silva et 
al. (2010) showed that amprenavir reduced the expression 
of surface mannose- and sialic acid-rich glycoconjugates 
also inhibited esterase activity, sterol content and biofilm 
formation in C. albicans. The adhesion of Candida sp. 
may be related to surface glycoprotein or ion-bridging, 
especially with calcium ions, given these physical factors 
may be affected differentially by different protease inhibi-
tors (Tsang, Hong, 2009).
In summary, it is possible to conclude that the use of 
antiretroviral therapy in HIV-positive was associated with 
immune reconstitution as well as decreases in the preva-
lence of OC and candidal carriage. According to Pomarico 
et al. (2009), the protease inhibitors might have had an 
anti-candidiasis effect, resulting not only from immune 
reconstitution, but also from direct anti-yeast mechanisms.
Antiretroviral drugs and viral agents (Table II)
Antiretroviral therapy benefits patients who are 
co-infected by HIV, HHV-8 (Harrington et al., 1997; 
Hocqueloux et al., 2001; Lebbe et al., 1998; Wit, Sol, 
Renwick, 1998), EBV (Hocqueloux et al., 2001), HBV 
(Benhamou et al., 2001; Deal et al., 2002; Perillo et al., 
2000), parvovirus B19 (Mylonakis et al., 1999; Ware, 
Moore, 2001) and CMV (Borges et al., 2001; Deayton et 
al., 1999; Li et al., 1999).
It has been shown that HIV stimulates HHV-8 
replication in vitro (Harrington et al., 1997) and strong 
suppression of HIV replication by antiretroviral agents 
may thus indirectly suppress HHV-8. After 94 weeks of 
HAART treatment, a case report detected absolute cure 
from Kaposi sarcoma (KS), DNA clearance of HHV-8 in 
peripheral blood mononuclear cells and plasma, and an 
FIGURE 1 - Flow of studies for systematic review.
patients also infected by Candida spp. Since oral can-
didiasis (OC) is a particularly common infection in this 
patient group, it is noteworthy that HAART significantly 
decreases the amount of fungi in the oral cavity (Macura 
et al., 2002). A decrease in the prevalence of OC has also 
been coupled with a rise in CD4+ T-cell counts (Yang et 
al., 2006). The diminished exposure to Candida spp. was 
accompanied by decreases in levels of Candida-specific 
secretory immunoglobulin A (Pomarico, 2009).
In addition, the importance of secreted aspartic 
protease (SAP), an important virulence factor of Candida 
spp, has also been emphasized. HIV protease inhibitor, a 
common component of HAART, is an inhibitor of HIV 
protease, the enzyme required for correct processing of 
HIV’s retroviral precursor proteins. Previous research has 
evaluated the inhibitory activity of protease inhibitors (PI) 
for SAP during OC manifestations. The anti-SAP effect of 
PI-HAART (indinavir and ritonavir) has been associated 
with the clinical resolution of OC but not with late and in-
constant recovery of anticandidal cellular immunity (Cas-
sone et al., 2002). Although oral candidal isolates secrete 
protease, ritonavir does not inhibit all protease-secreting 
oral yeast isolates. Nevertheless, it decreases the percent-
age of Candida spp. isolates, particularly C. albicans, 
which is resistant to anti-fungal agents (amphotericin B, 
fluorocitosine, fluoconazole, ketoconazole and itracon-
azole). This is perhaps due to the synergic effect between 
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TABLE I - Characteristics of studies included in the systematic review, on antiretroviral agents and fungi
Source Aim Study design Drug groups Patients (n) Conclusion
Macura et al.
Folia Med. 
Cracov., 
2002.
Evaluate impact of 
antiretroviral therapy on 
development of oral mucosa 
mycosis in HIV patients.
Controlled 
clinical trial
PI
NNRTI
75 ARV in HIV patients 
significantly reduced the number 
of fungi present in oral cavity.
Yang et 
al. BMC 
Infectious 
Disease, 
2006.
Determine effect of prolonged 
HAART on oropharyngeal 
candidiasis and colonization 
with Candida species in 
Taiwan.
Prospective HAART 142 HAART was highly effective for 
decreasing oral candidiasis in 
association with a rise in CD4+ 
T-cell count.
Cassone et al.
J. Infect. Dis. 
2002.
Compare effects of IP 
and NNRTIs in SAP in C. 
albicans.
Cross-sectional 
and longitudinal.
PI
NNRTI
60 PIs apply an early, immune 
reconstitution-independent effect 
on Candida virulence in oral 
cavities of HIV-positive subjects.
Migliorati 
et al.
Oral Surg. 
Oral Med. 
Oral Pathol. 
Oral Radiol. 
Endod., 2004.
Evaluate ritonavir’s anti-
fungal activities, principally 
in oral candidal isolates that 
secrete protease.
Clinical trial PI 19 Ritonavir does not inhibit all 
protease-secreting oral yeast 
isolates. 
Arribas et al.
AIDS, 2000.
This study determined 
the relationship between 
antiretroviral therapy and 
changes in prevalence and 
amount of oropharyngeal 
candidiasis (OPC) and skin 
test reactivity for delayed 
hypersensitivity type.
Observational 
cohort
PI
NRTI
99 In patients with advanced HIV 
infection, antiretroviral therapy 
including a protease inhibitor 
has a positive impact on natural 
history of OPC. 
Hoegl et al.
Mycoses, 
1998.
Evaluate the effects of 
treatment with an HIV 
protease inhibitor (PI) on oral 
candidiasis.
Retrospective 
and prospective
PI
NRTI
62 Absence of Candida 
colonization and manifest oral 
candidiasis was observed only in 
patients with elevation of CD4+ 
T-cells after PI.
Protease inhibitor (PI); Nonnucleoside reverse-transcriptase inhibitors (NNRTI); Nucleoside analog reverse-transcriptase inhibitors 
(NRTI), Highly active antiretroviral therapy (HAART); Antiretroviral therapy (ARV).
improvement in the patient’s immunological condition 
(Wit, Sol, Renwick, 1998). A cohort study with ten patients 
also showed KS/ DNA clearance of HHV-8 in HIV patients 
after immune reconstitution with antiretroviral therapy 
containing a protease inhibitor. Antiretroviral therapy 
has been effective in KS regression and HHV-8 viraemia 
negation condition (Lebbe et al., 1998).
Primary effusion lymphoma (PEL) is a rare HIV-
associated cancer which may be caused by HHV-8 and 
EBV infection. A case report of a HAART-treated AIDS 
patient showed complete PEL clearance and decrease in 
HHV-8-DNA and EBV-DNA to negligible levels. When 
chemotherapy is contraindicated, HAART becomes a vi-
able alternative (Hocqueloux et al., 2001).
There is evidence that the AZT (azidothymidine) 
and valganciclovir association design targeting cells with 
lytic Kaposi sarcoma herpes virus (KSHV) replication also 
has activity in KSHV- associated multicentric Castleman 
disease (MCD) (Uldrick et al., 2011). AZT and interferon-
alpha (IFN-α) induced apoptosis in HHV-8+/EBV− PEL 
cells in culture, by induction of a tumor necrosis factor-
related apoptosis inducing ligand (TRAIL) mediated 
suicide program (Wu et al., 2005). 
EBV-associated immunoblastic lymphoma occurs 
in immunocompromised patients such as those with AIDS 
where Dewan et al. (2009) observed that ritonavir induced 
Activity of antiretroviral drugs in human infections by opportunistic agents 175
cell-cycle arrest at the G1-phase as well as apoptosis 
through down-regulation of cell-cycle gene cyclin D2 
and antiapoptotic gene survivin. Furthermore, ritonavir 
suppressed transcriptional activation of nuclear factor-
kappaB (NF-κB) in these cells. AZT inhibits NF-κB and 
up-regulates EBV gene expression in primary Epstein-
Barr virus–positive Burkitt lymphoma (EBV-BL) lines 
(Kurokawa et al., 2005). 
Lamivudine (3TC), a nucleoside analogue reverse 
transcriptase inhibitor of HIV and HBV DNA polymerase, 
is used in the long-term treatment of HBV chronic hepatitis 
because of its effectiveness and good tolerability. Research 
TABLE II - Characteristics of studies included in the systematic review, on antiretroviral agents and virus
Source Aim Study design Drug groups Patients (n) Conclusion
Wit et al.
AIDS, 1998.
Describe a case of complete 
regression of AIDS-related 
KS and clearance of HHV-8 
DNA after initiation of ARV.
Case report NRTI 1 Clearance of HHV-8 DNA 
from both peripheral blood 
mononuclear cells and plasma 
after initiation of antiretroviral 
therapy.
Lebbé et al.
AIDS, 1998.
Correlate clinical and 
biological response of IP 
with HIV-associated Kaposi’s 
sarcoma.
Prospective NRTI
PI
10 Antiviral therapy with protease 
inhibitors is clinically effective 
in HIV-associated Kaposi’s 
sarcoma.
Hocqueloux 
et al.
AIDS, 2001.
Analyze remission of primary 
lymphoma effusion in 
HAART-subjected patient.
Case report PI
NRTI NNRTI
1 Complete remission of primary 
effusion lymphoma.
Deal et al.
Ann. Biol. 
Clin., 2002.
Evaluate treatment with 
lamivudine in HIV patients 
co-infected by HBV.
Controlled 
clinical trial
NRTI 34 Long-term efficacy of 
lamivudine in HBV-infected 
patients was proven.
Mylonakis 
et al.
Am. J. 
Hematol., 
1999.
Report on remission of 
parvovirus B-19-infected 
patient with aplasia, prior to 
HAART treatment.
Case report PI
NRTI
1 CD4+ T-cells count 
progressively increased, and 
DNA polymerase chain reaction 
for parvovirus B19 became 
undetectable.
Ware, Moore.
Clin. Infect. 
Dis., 2001.
Describe solution of chronic 
parvovirus B-19-infected 
patient with AIDS when 
HAART is employed.
Case report PI
NRTI
1 Serologic evidence of 
eradication of parvovirus 
after having received 
effective treatment for human 
immunodeficiency virus 
infection.
Deayton et al.
AIDS, 1999.
Determine effect of HAART 
on cytomegalovirus viraemia 
and retinitis.
Prospective NRTI
PI
16 HAART including a protease 
inhibitor can result in complete 
suppression of CMV viraemia.
Borges et al.
Int. J. STD 
AIDS, 2001.
Evaluate effectiveness of ARV 
on cytomegalovirus viraemia 
in AIDS patients.
Prospective PI
NRTI
70 HAART induces immunological 
improvement and can be 
associated with negativity of 
CMV antigenaemia.
Li et al.
J. Acquir. 
Immune 
Defic. 
Syndr. Hum. 
Retrovirol., 
1999.
Report improvement of an 
HIV and cytomegalovirus 
patient after treatment with 
ARV.
Case report PI
NRTI
1 Negative result of CMV blood 
culture with restoration of CD4+ 
T-cell reactivity to CMV after 
HAART.
Protease inhibitor (PI); Nonnucleoside reverse-transcriptase inhibitors (NNRTI); Nucleoside analog reverse-transcriptase inhibitors 
(NRTI), Highly active antiretroviral therapy (HAART), Antiretroviral therapy (ARV).
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with HBV-DNA detection-sensitive techniques has dem-
onstrated the effectiveness of lamivudine in co-infected 
HIV patients over a long period of time (Deal et al., 2002). 
However, resistant mutants occur during treatment and 
also for HIV, corresponding to changes of methionine for 
isoleucine and valine in the YMDD domain C sequence of 
the enzyme (Deal et al., 2002). Other drugs such as tenofo-
vir and adefovir dipivoxil can show beneficial associations 
with HAART in the treatment of lamivudine-resistant 
hepatitis B (Benhamou et al., 2001; Perillo et al., 2000). 
There are potentially more effective drugs or combina-
tion therapies, which can reduce intrahepatic covalently 
closed circular DNA (cccDNA) effectively in chronic B 
hepatitis patients (Kumar et al., 2011; Reijnders et al., 
2010; Shinkai et al., 2006; Sung et al., 2005).
Other studies report virus clearance by parvovirus 
B19 in HIV-infected people after HAART application. 
The first case report showed the clearance of parvovirus 
B19 in a patient with red blood aplasia and severe anemia 
some two months after the start of antiretroviral therapy, 
that was not eradicated after conventional treatment with 
intravenous immunoglobulin (IVIG) (Ware, Moore, 2001). 
The second study showed that overall clearance in the 
serum of a parvovirus B19-chronic anemia case occurred 
after 14 months of HAART. Thus, antiretrovirals can be 
effective and possibly eliminate transfusions and IVIG 
therapy in HIV co-infected individuals (Mylonakis et al., 
1999). This may be associated with the immune recon-
stitution syndrome (IRS). In 2005, the first case of IRS 
associated with B19-induced chronic pure red cell aplasia 
during highly active antiretroviral therapy was described 
(Intalapaporn et al., 2005). 
HAART use, coupled with PI, may require complete 
suppression of CMV. This response was correlated with 
protection against CMV retinitis in a group of patients fea-
turing high risk for the development of the disease (Deya-
ton et al., 1999). Antiretroviral therapy may also result in 
negative antigenemia and culture for CMV, immunologi-
cal improvement through increased CD4+ T-cell count, 
increase in reactivity of CD4+ T-cells for CMV antigens 
and reduction in HIV load (Borges et al., 2001; Li et al., 
1999). Criteria for discontinuation of treatment for CMV 
when the patient is receiving HAART for several months 
requires further investigation by prospective studies (Li 
et al., 1999). To our knowledge, there are no articles de-
scribing the direct activity of antiretroviral drugs on CMV.
Antiretroviral drugs and bacterial agents (Table III)
Respiratory tract bacterial (pyogenic and non-
pyogenic) infections in human immunodeficiency 
virus-infected patients are the most frequent respiratory 
disease but other sites may also be compromised. In the 
pre-HAART era the incidence of most common opportu-
nistic infections such as bronchitis and pneumonia could 
be partially prevented by the use of prophylaxis (Mayaud, 
Parrot, Cadranel, 2002). According to these authors the 
main pyogenic bacteria responsible for pneumonia in these 
patients were Streptococcus pneumoniae and, to a lesser 
degree, Haemophilus influenzae, in adults as well as chil-
dren in both developed and developing countries. In the 
HAART era, some studies have observed a decrease in the 
number of cases of bacterial pneumonia (Mayaud, Parrot, 
Cadranel, 2002), while other authors (Tumbarello et al., 
1999) have shown that this decrease was mainly observed 
for nosocomial pneumonia and remained nonsignificant 
for community-acquired pneumonia.
HAART has also led to a significant reduction in the 
incidence, and in changes of characteristics, of bactere-
mia by etiological agents such as Staphylococcus aureus 
(28%), coagulase negative Staphylococcus (13%), non-
typhoid (NT) species of Salmonella (11%), Streptococ-
cus pneumoniae (11%), Pseudomonas aeruginosa (11%) 
(Tumbarello et al., 2000). The incidence of Non-typhoidal 
Salmonella (NTS) and Campylobacter have declined since 
the introduction of HAART (Larsen et al., 2011). A decline 
in incidence of nosocomial bacterial pneumonia (NBP) 
caused by Pseudomonas aeruginosa, Staphylococcus 
aureus and Streptococcus pneumoniae in HIV-infected in-
dividuals was observed after the introduction of HAART. 
S. aureus and P. aeruginosa were the leading causes of 
NBP, but the frequency of pneumococcal pneumonia was 
also significant (Franzett et al., 2006).
A study carried out at a central hospital in Malawi 
(Africa) during the period of national scale-up of anti-
retroviral therapy and cotrimoxazole prophylaxis, dem-
onstrated a downward trend in invasive pneumococcal 
disease (IPD) (Everett et al., 2011). Although HAART has 
been associated with significant decline in IPD morbidity 
and mortality, HIV-infected African children with access 
to HAART remain a high-risk group for IPD (Nunes et 
al., 2011).
HIV increases the risk of immediate tuberculosis 
(TB) progress soon after infection or re-infection with 
Mycobacterium tuberculosis (MTB) and of reactivating 
a latent MTB. HAART decreased the incidence of MTB 
infections and death among patients with AIDS, although 
some patients experienced temporary worsening of TB 
(Leone et al., 2010). This phenomenon termed Immune 
Reconstitution Inflammatory Syndrome (IRIS) is caused 
by the introduction of HAART, where immune recovery 
may result in immunological reactions and clinical dete-
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rioration in patients with TB (Lawn, Bekler, Meller, 2000). 
Baalwa et al. (2008) discussed a possible limitation in the 
protective effects of HAART against TB recurrence and 
reiterated the need to consider TB chemoprophylaxis as a 
supplement to reduce TB in patients from endemic regions.
The initiation of HAART after starting TB treat-
ment involves many variables such as drug tolerance, 
drug co-toxicities, pharmacokinetic drug interactions, 
polypharmacy impacts on adherence, high pill burden, 
and the immune reconstitution inflammatory syndrome 
(IRIS), thus complicating the management of co-infected 
individuals (Piggott, Karakousis, 2011; Wood, 2010). 
Perturbations of the innate and adaptive immune response 
to M. tuberculosis before and during antiretroviral therapy 
(ARV) may contribute to the immunopathology of tuber-
culosis-associated immune reconstitution inflammatory 
syndrome (TB-IRIS) (Oliver et al., 2010; Tadokera et al., 
2011). Hypercytokinaemia appears to be involved with 
TB-IRIS, because higher interleukin (IL)-18, IL-6 and 
tumour necrosis factor (TNF) (Oliver et al., 2010; Tado-
kera et al., 2011) and type 1 effector T cell responses are 
noted in ARV-associated tuberculosis (Elliott et al., 2009).
Relevant reduction in the incidence of other myco-
bacteria such as Mycobacterium avium complex (MAC) 
has been reported among HIV-infected patients. The 
introduction of HAART, although partially explaining 
some of the decrease in MAC during a certain period, a 
significantly lower risk of MAC than expected remained 
(Kirk et al., 2000). A study showed that a 74% reduction in 
the rate of new MAC infections occurred following wide-
spread use of HAART (Tumbarello et al., 2001). The use 
of protease inhibitor-containing regimens was associated 
with a decreased risk of bacterial pneumonia (risk ratio 
[RR] 0.55, 95% CI 0.31 to 0.94) (Sullivan et al., 2000). 
Mycobacterium haemophilum was identified as 
the local agent of skin infection in an AIDS patient, and 
clinical cure was achieved only after reconstitution of im-
munity by HAART, although this has not been observed 
in clinical outcomes of patients with the invasive form 
of the disease (Paech et al., 2002). However, clinical 
manifestation was observed in patients presenting latent 
infection with Mycobacterium xenopi (Bachmeyer et al., 
2002; Dronda et al., 2000; Manfredi et al., 2003) and My-
cobacterium kansasii (Ito et al., 2009) after reconstitution 
TABLE III - Characteristics of studies included in the systematic review, on antiretroviral agents and bacteria
Source Aim Study design Drug groups Patients (n) Conclusion
Kirk et al.
Am. J. Respir. 
Crit. Care 
Med., 2000.
Evaluate effectiveness of 
HAART in Mycobacterium 
tuberculosis and M. avium-
infected HIV patients.
Cohort HAART 7,000 Decrease in TB was associated 
with introduction of HAART and 
changes in CD4+ T-cell count.
Tumbarello 
et al.
Eur. J. Clin. 
Microbiol. 
Infect. Dis., 
2001.
Evaluate effectiveness of 
HAART on infection spread 
by Mycobacterium avium in 
HIV patients.
Case-control HAART 81 MAC infections are less frequent 
in HAART era, but remain 
responsible for cases of severe 
disease.
Tumbarello 
et al.
J. Acquir. 
Immune 
Defic. Syndr., 
2000.
Evaluate incidence of 
bacteremia in HIV-infected 
subjects after introduction of 
HAART and describe patients’ 
characteristics.
Case-control PI
NRTI
174 HAART promotes a significant 
reduction in the incidence, and 
in changes of characteristics, of 
bacteremia.
Paech et al
Clin. Infect. 
Dis., 2002.
Evaluate effectiveness of 
HAART treatment by M. 
haemophilum co-infection.
Case report PI
NRTI
1 A local M. haemophilum skin 
infection resolved as a result of 
successful antiretroviral therapy 
only.
Dronda et al.
Rev. Clin. 
Esp., 2000. 
Describe patient with 
Mycobacterium xenopi lung 
infection.
Case report PI
NRTI
1 A possible latent infection 
was expressed clinically after 
immune reconstitution induced 
by the treatment.
Protease inhibitor (PI); Nucleoside analog reverse-transcriptase inhibitors (NRTI), Highly active antiretroviral therapy (HAART). 
MAC: Mycobacterium avium complex.
I. G. Demarchi, D. M. Cardozo, S. M. A. Aristides, R. A. Moliterno, T. G. V. Silveira, R. F. Cardoso, D. A. Bertolini, T. I. E. Svidzinski1 et al.178
of immunity by antiretroviral therapy. The isolation of 
pulmonary M. xenopi in an HIV-1 infected population is 
usually associated with severe immune suppression and 
the presence of other pathogens. In most cases, patients in 
use of HAART have potent immune reconstitution that is 
sufficient, dispensing with the need for antimycobacterial 
drugs. Mortality rates among these patients seems to be 
significantly lower than previously reported (Kerbiriou 
et al., 2003). 
HIV-Mycobacterium leprae interaction is different 
from that described above. HIV infection has not been 
reported to increase susceptibility to leprosy or have a 
significant effect on the pathogenesis of neural or skin 
lesions. On the other hand, the initiation of HAART in 
HIV-leprosy patient has been reported to be associated 
with activation of subclinical infection and exacerbation 
of existing leprosy lesions. Chow et al. (2009) reported 
a case of IRIS in a patient co-infected with HIV and M. 
leprae, presenting as an exacerbation of Hansen’s Disease 
where the patient’s skin lesions progressed from borderline 
tuberculoid to lepromatous leprosy following ARV initia-
tion. Other publications have also reported the presence 
of IRIS in HIV-Mycobacterium leprae patients (Couppie 
et al., 2004; Lawn, Wood, Lockwood, 2003; Pignatato et 
al., 2004; Visco-Comandini, et al., 2004).
Antiretroviral drugs and protozoa agents (Table IV)
Combination antiretroviral therapy has been able to 
modify the natural history of opportunistic diseases, such 
as cryptosporidiosis and microsporidiosis (Maggi et al., 
2000). AIDS-related Enterocytozoon bieneusi and Cryp-
tosporidium parvum may be cured following successful 
antiretroviral therapy (Miao et al., 2000), but infection 
eradication might not always be possible (Maggi et al., 
2000). Protease inhibitors may be capable of eradicat-
ing Microsporidium and/or Criptosporidium, which are 
refractory to other treatments, and this effect may involve 
partial restoration of immune function due to the inhibi-
tion of HIV replication (Bobin et al., 1998). Miao et al. 
(2000) prospectively followed up HIV-positive patients 
with diarrheal symptoms caused by cryptosporidia or 
microsporidia and observed that patients who responded 
successfully to HAART eradicated both organisms pro-
moting improved symptoms within one month of therapy. 
Complete eradication of the organisms however, was 
only observed after 6 months of treatment. Combination 
antiretroviral therapy that includes a PI may restore im-
munity and result in complete clinical, microbiological, 
and histological responses to Enterocytozoon bieneusi and 
Cryptosporidium parvum in HIV-1 infected individuals 
(Carr et al., 1998). Findings show rapid repopulation of 
the intestinal mucosa with CD4+ T cells after initiation of 
HAART, which can effectively restore mucosal immunity, 
leading to the eradication of Cryptosporidium parvum 
(Carr et al., 1998). Indinavir directly affects the cycle 
of C. parvum, evidenced by marked reduction in oocyst 
shedding and number of intracellular parasites on in vitro 
and in vivo models (Mele et al., 2003).
In 2001, Casado et al. determined the evolution of 
visceral leishmaniasis (VL) in 10 consecutive patients 
co-infected with HIV, taking into account the decline in 
the incidence of opportunistic infections after the introduc-
tion of protease inhibitor therapy. Giudice et al, (2002) 
estimated the incidence of HIV–Leishmania coinfections 
in a French hospital, and showed a decreased from 11.6 ± 
1.2 per 10,000 persons-years before 1996 to 6.3 ± 0.7 per 
10,000 persons-years after 1996, the year when HAART 
was introduced in France. Factors other than restoration 
of immune function might also account for the decline in 
the incidence of VL. PIs have shown antimicrobial proper-
ties, such as anticandidal and antitoxoplasmic activities, 
in vitro.
Some studies have reported antiprotozoal activity 
of HAART in Leishmania (Araújo et al., 2011; Kumar et 
al., 2008; Santos et al., 2009; Savoia, Allice, Tovo, 2005; 
Valdivieso et al., 2010). AZT significantly decreased the 
number of Leishmania parasites due to its toxicity and 
caused morphometric alterations such as an increase in 
width of the body, cytoplasmic granulation and vacuoliza-
tion (Araújo et al., 2011). PIs such as ritonavir, indinavir 
and saquinavir have reduced the number of Leishmania 
promastigotes in vitro (Savoia, Allice, Tovo, 2005). Fur-
thermore, PIs seem to reduce the intracellular growth 
of Leishmania parasites in human primary monocyte-
derived macrophages (MDMs) coinfected with HIV-1 
(Trudel et al., 2008) and can also induce oxidative stress-
mediated, caspase-independent apoptosis in Leishmania 
amastigotes (Kumar et al., 2010). Valdivieso et al. (2010) 
reported an antiproliferative effect on Leishmania sp. 
promastigotes, axenic amastigotes and co-infected HIV/
Leishmania monocytes and amastigotes of Leishmania 
per macrophage by saquinavir mesylate and nelfinavir. 
This outcome appears to be the result of cell division 
block. In addition, PIs can promote profound changes in 
Leishmania ultrastructure such as cytoplasm shrinking, 
increase in the number of lipid inclusions with some cells 
presenting the nucleus closely wrapped by endoplasmic 
reticulum resembling an autophagic process, as well as 
chromatin condensation, suggestive of apoptotic death 
(Santos et al., 2009).
Analysis of therapy-induced changes in the mucosal 
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TABLE IV - Characteristics of studies included in the systematic review, on antiretroviral agents and protozoa
Source Aim Study design Drug groups Patients (n) Conclusion
Miao et al.
JAIDS, 2000. 
Determine whether the 
parasites cryptosporidia and 
microsporidia were effectively 
eradicated or supply 
suppressed after HAART.
Prospective NRTI
PI
6 AIDS-related cryptosporidiosis 
and microsporidiosis can be 
cured following successful 
antiretroviral therapy
Bobin et al.
Path. Biol., 
1998.
Evaluate ARV effect on 
evolution of diarrhea caused 
by Microsporidium and 
Criptosporidium in HIV 
patients.
Prospective PI 20 PI may be capable of eradicating 
Microsporidium and/or 
Criptosporidium infection 
refractory to other treatments. 
Carr et al. 
Lancet, 1998.
Demonstrate that combination 
PI and NRTIs may improve 
immunity with regard to E. 
bieneusi and C. parvum.
Prospective NRTI
PI
9 This combination can restore 
immunity to E.bieneusi or 
C. parvum in HIV-1 infected 
individuals.
Schmidt et al.
Gastroen-
terology, 
2001. 
Evaluate effectiveness of 
HAART with PI against C. 
parvum.
Case report NRTI
PI
1 HAART has led to clinical 
recovery and eradication of 
cryptosporidiosis. This could 
be due to decreased HIV RNA 
below the detection limit and 
increase in CD4 T cells.
Maggi et al.
Eur. J. Clin. 
Microbiol. 
Infect. Dis., 
2000.
Evaluate response to 
antimicrobial treatment 
of HIV-1 associated 
microsporidiosis and 
cryptosporidiosis in patients 
with or without previous 
antiretroviral treatment.
Retrospective NRTI
PI
50 Combination antiretroviral 
therapy may be able to greatly 
modify the course of these 
diseases in patients infected with 
HIV-1.
Protease inhibitor (PI); Highly active antiretroviral therapy (HAART); Nucleoside analog reverse-transcriptase inhibitors (NRTI); 
Antiretroviral therapy (ARV).
immune response of these patients may provide significant 
clues to the mechanisms involved in the control of enteric 
opportunistic agents (Schimdt et al., 2001). Similarly, 
persistent CD8+ T-cells and macrophage infiltrate plus the 
rapid relapse time in patients with declining CD4+ T-cells 
counts suggest that neither infection was eradicated (Carr 
et al., 2000). 
Restoration of immune responses to Toxoplasma 
gondii, a major opportunistic pathogen in patients with 
AIDS, has also been reported in patients receiving HAART 
(Derouin and Santillana-Hayat, 2000). Pozio and Morales 
(2005) have reported that the use of PIs resulted in marked 
decrease in toxoplasmic encephalitis among HIV-positive 
individuals.
Furco et al. (2008) showed that specific immune re-
constitution against T. gondii occurred in most HIV-infect-
ed patients with a low baseline CD4+ T-cell count after 12 
months of HAART. However, a significant proportion of 
these patients did not present a normal lymphoproliferative 
response or IFN-γ production to the Toxoplasma antigen. 
These data will also promote better understanding of the 
determinants of restoration of T. gondii-specific immune 
responses in patients with AIDS starting on HAART. Der-
ouin and Santillana-Hayat (2000) showed that nucleoside 
analogs had no effect on T.gondii growth in vitro, whereas 
ritonavir and nelfinavir were inhibitory for Toxoplasma.
CONCLUDING REMARKS
Current finding are highly relevant for clinical medi-
cine and may serve to reduce the number of prescribed 
drugs thereby improving the quality of life of patients 
with opportunistic diseases. The present systematic re-
view identified several opportunistic agents of the oral 
cavity subjected to the positive activities of HAART thus 
decreasing the number of fungi, favoring SAP inhibition, 
and improving laboratory and immunological param-
eters. In the case of viruses, antiretroviral therapy may be 
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beneficial for patients co-infected by HIV, HHV-8, EBV, 
HBV, parvovirus B19 and CMV. The incidence of Myco-
bacterium tuberculosis, Mycobacterium avium complex, 
Microsporidium and/or Criptosporidium, refractory to 
other treatments was significantly reduced. Protease in-
hibitors are of paramount importance among those drugs 
currently used in HAART. 
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